Table 5. Analysis of pre-treatment factors associated with circumferential margin involvement.
| Factor | Odds ratio | 95% CI | P -value |
|---|---|---|---|
| Univariate analysis | |||
| EUS T stage | |||
| T1/T2 | Reference group | ||
| T3/T4 | 8.726 | 3.798–20.050 | <0.0001 |
| EUS N stage | |||
| N0 | Reference group | ||
| N1 | 1.781 | 1.060–2.992 | 0.029 |
| EUS tumour length | 1.173 | 1.056–1.303 | 0.003 |
| EUS disease length | 1.087 | 1.013–1.167 | 0.020 |
| EUS tumour thickness | 1.795 | 0.974–3.309 | 0.061 |
| EUS LNMC | 1.156 | 1.033–1.294 | 0.012 |
| Neo Tx | |||
| S | Reference group | ||
| CS | 2.468 | 1.410–4.322 | 0.002 |
| CRTS | 0.310 | 0.111–0.869 | 0.026 |
| Multivariate analysis | |||
| EUS T stage | |||
| T1/T2 | Reference group | ||
| T3/T4 | 24.313 | 7.438–79.476 | <0.0001 |
| Neo Tx | |||
| S | Reference group | ||
| CS | 0.641 | 0.289–1.420 | 0.273 |
| CRTS | 0.116 | 0.035–0.382 | <0.0001 |
Abbreviations: 95% CI=95% confidence interval; CRM=circumferential resection margin; CRTS=neoadjuvant chemoradiotherapy; CS=neoadjuvant chemotherapy; EUS=endoluminal ultrasonography; LNMC=lymph node metastasis count; neo Tx=neoadjuvant treatment type; S=surgery alone.